ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04434989 (Stereotactic Body Radiotherapy Versus Ablation for Perivascular Hepatocellular Carcinoma), which is not on this map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stereotactic Body Radiotherapy Versus Ablation for Perivascular Hepatocellular Carcinoma: A Phase 2, Multicenter, Randomized Controlled Trial
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Irreversible electroporation vs. stereotactic body radiotherapy for solitary hepatocellular carcinoma ≤5 cm: A multicenter retrospective study.JHEP reports : innovation in hepatology · 2026Article
- Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.Radiation oncology (London, England) · 2026Article
- First randomized controlled trial comparing stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: lessons and key considerations for interpretation of results.Hepatobiliary surgery and nutrition · 2026Article
- Stereotactic body radiotherapy in early-stage hepatocellular carcinoma: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- External beam radiation for HCC: Ready for incorporation into guidelines?JHEP reports : innovation in hepatology · 2026Review
- Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.Frontiers in oncology · 2026Review
- FOXP1-transcriptionally regulated AEG-1 enhances tumor cell stemness to promote hepatocellular carcinoma radioresistance.Molecular and cellular biochemistry · 2026Article
- Deubiquitinase USP28 promotes the malignant progression and radio-resistance of hepatocellular carcinoma by stabilizing WDHD1.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Integrin β6/Annexin A2 axis triggers autophagy to orchestrate hepatocellular carcinoma radioresistance.Cell death and differentiation · 2025Article
- METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression.Cell death & disease · 2025Article
- Expanding Indications for Liver Transplantation in the Treatment of Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2024Review
- Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review.Journal of liver cancer · 2024Article
- Radiofrequency Ablation Therapy versus Stereotactic Body Radiation Therapy for Naive Hepatocellular Carcinoma (≤5cm): A Retrospective Multi-Center Study.Journal of hepatocellular carcinoma · 2024Article
- Efficacy of transcatheter arterial chemoembolization combined with radiotherapy for locally advanced hepatocellular carcinoma.American journal of translational research · 2024Article
- Deep learning based automatic internal gross target volume delineation from 4D-CT of hepatocellular carcinoma patients.Journal of applied clinical medical physics · 2024Article
- Risk prediction and treatment assessment in glioma patients using SEER database: a prospective observational study.BMJ open · 2023Observational
- Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis.Clinical and molecular hepatology · 2023Article
- Proton Beam Therapy versus Radiofrequency Ablation for Patients with Treatment-Naïve Single Hepatocellular Carcinoma: A Propensity Score Analysis.Liver cancer · 2023Article
- Breakthroughs in Hepatocellular Carcinoma Therapies.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose Data that guide selection of optimal local ablative therapy for the management localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective comparative data for these treatment modalities, we aimed to compare the effectiveness of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) by using the National Cancer Database. Methods We conducted an observational study to compare the effectiveness of RFA versus SBRT in nonsurgically managed patients with stage I or II HCC. Overall survival was compared by using propensity score-weighted and propensity score-matched analyses based on patient-, facility-, and tumor-level characteristics. A sensitivity analysis was performed to evaluate the effect of severe fibrosis/cirrhosis. In addition, we performed exploratory analyses to determine the effectiveness of RFA and SBRT in clinically relevant patient subsets. Results Overall, 3,684 (92.6%) and 296 (7.4%) nonsurgically managed patients with stage I or II HCC received RFA or SBRT, respectively. After propensity matching, 5-year overall survival was 29.8% (95% CI, 24.5% to 35.3%) in the RFA group versus 19.3% (95% CI, 13.5% to 25.9%) in the SBRT group ( P < .001). Inverse probability-weighted analysis yielded similar results. The benefit of RFA was consistent across all subgroups examined and was robust to the effects of severe fibrosis/cirrhosis. Conclusion Our study suggests that treatment with RFA yields superior survival compared with SBRT for nonsurgically managed patients with stage I or II HCC. Even though our results are limited by the biases related to the retrospective study design, we believe that, in the absence of a randomized clinical trial, our findings should be considered when recommending local ablative therapy for localized unresectable HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.